SCHEMBL2608545

SCHEMBL2608545

CCOC(=O)C1Cc2ccncc2N1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 3/20 0.43
KDM4E B2RXH2 4/20 0.41
MAPT P10636 3/20 0.41
ALDH1A1 P00352 3/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
GAA P10253 3/20 0.39
HSD17B10 Q99714 2/20 0.37
CYP1A2 P05177 2/20 0.37
CYP2D6 P10635 2/20 0.37
CYP2C19 P33261 2/20 0.37
CYP2C9 P11712 1/20 0.37
MAPK1 P28482 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
HPGD P15428 1/20 0.37
ELANE P08246 1/20 0.36
NPEPPS P55786 1/20 0.36
POLB P06746 1/20 0.36
KDM5A P29375 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13593679 0.90 NAMPT (0.45) NAMPTKDM4EMAPTALDH1A1CASP1
SCHEMBL23099668 0.85 NAMPT (0.38) NAMPTKDM4EMAPTALDH1A1CASP1
SCHEMBL14401106 0.81 KMT2A (0.40) NAMPTKDM4EMAPTALDH1A1CASP1
SCHEMBL3182006 0.80 GAA (0.59) KDM4EMAPTALDH1A1GAAHSD17B10
SCHEMBL10334541 0.80 GAA (0.59) KDM4EMAPTALDH1A1GAAHSD17B10
SCHEMBL3255783 0.80 GAA (0.59) KDM4EMAPTALDH1A1GAAHSD17B10
SCHEMBL30562957 0.80 GAA (0.59) KDM4EMAPTALDH1A1GAAHSD17B10
SCHEMBL30213277 0.80 GAA (0.59) KDM4EMAPTALDH1A1GAAHSD17B10
SCHEMBL30104029 0.80 GAA (0.59) KDM4EMAPTALDH1A1GAAHSD17B10
Hydrochloric Acid SCHEMBL10956908 0.80 MAPT (0.55) KDM4EMAPTALDH1A1GAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8158622-B2 Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase PROSIDION LIMITED (GB) 2012-04-17 US disclosed
US-20090023703-A1 Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase PROSIDION LIMITED (GB) 2009-01-22 US disclosed
US-7405210-B2 Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase OSI PHARMACEUTICALS, INC. (US) 2008-07-29 US disclosed
US-20070244090-A9 PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE BRADLEY STUART E 2007-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244090-A9 PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE PYGL, PYGM, PYGB NAMPT 676/4885KDM4E 2422/4885MAPT 2202/4885
US-20090023703-A1 Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase PYGL, PYGM, PYGB NAMPT 676/4885KDM4E 2422/4885MAPT 2202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.